Join the #FierceMadness!
Pick your favorite drug names in this year's tournament challenge. Read more and vote here!
The problems at a Celltrion plant that threaten Teva's fremanezumab launch may be less limited than the company had hoped, analysts say.
Takeda has rolled out Entyvio in multiple Asia-Pacific countries, but the Japanese drugmaker envisions even more growth in the region.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
After a bruising two-day play-in, Taltz and Nerlyx are among the victors in our first round of this year’s drug name tournament challenge.
As four of pharma's top five advertisers cut spending, DTC outlays dropped in 2017 for the first time since the 2008 recession, Kantar says.
Novartis' canakinumab, a rare disease med it's studying for the heart, cut CV risks in patients with diabetes and chronic kidney disease, data shows.
After last year’s successful DTC showdown, #FierceMadness is going back to its roots as a quest to determine the best new drug name.
AstraZeneca's Imfinzi won't have its first-line lung cancer data till later than expected, and at a time when Merck's Keytruda is racing ahead.
While unbranded pharma ads can be easier to pull off—or at least easier to get through medical and legal review—the same marketing rules apply.
With a new study in patients with peripheral artery disease, Johnson & Johnson has once again bolstered its case for another Xarelto approval.
With some new Plavix-matching data, AstraZeneca may have just found a new niche for its blood thinner Brilinta.